Cytoskeletal Signaling

β-Actin Blocking Peptide

イイネ!(0) β-Actin Blocking Peptide Data Sheet PDF
CSTコード 包装
希望納入価格 (円)
国内在庫 i
2012年2月9日11時30分 現在
ご登録代理店情報 i
カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更はこちら
#1025S100 μg16,000
ログインすると国内在庫状況がご確認いただけます。

Actin抗体製品一覧

用途
免疫組織染色
貯法
-20℃
使用目的
β-Actin (13E5) Rabbit mAb (#4970) の反応をブロックし、抗体の反応特異性を確認するために使用
社内データ

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using β-Actin (13E5) Rabbit mAb #4970 in the presence of control peptide (left) or β-Actin Blocking Peptide (right).

バックグラウンド

Actin, a ubiquitous eukaryotic protein, is the major component of the cytoskeleton. At least six isoforms are known in mammals. Nonmuscle β- and γ-actin, also known as cytoplasmic actin, are predominantly expressed in nonmuscle cells, controlling cell structure and motility (1). α-cardiac and α-skeletal actin are expressed in striated cardiac and skeletal muscles, respectively; two smooth muscle actins, α- and γ-actin, are found primarily in vascular smooth muscle and enteric smooth muscle, respectively. These actin isoforms regulate the contractile potential of muscle cells (1). Actin exists mainly as a fibrous polymer, F-actin. In response to cytoskeletal reorganizing signals during processes such as cytokinesis, endocytosis, or stress, cofilin promotes fragmentation and depolymerization of F-actin, resulting in an increase in the monomeric globular form, G-actin (2). The Arp2/3 complex stabilizes F-actin fragments and promotes formation of new actin filaments (2). It has been reported that actin is hyperphosphorylated in primary breast tumors (3). Cleavage of actin under apoptotic conditions has been observed in vitro and in cardiac and skeletal muscle (4-6). Actin cleavage by caspase-3 may accelerate ubiquitin/proteasome-dependent muscle proteolysis (6).

  1. Herman, I.M. (1993) Curr. Opin. Cell Biol. 5, 48-55.
  2. Condeelis, J. (2001) Trends Cell Biol. 11, 288-293.
  3. Lim, Y.P. et al. (2004) Clin. Cancer Res. 10, 3980-3987.
  4. Kayalar, C. et al. (1996) Proc. Natl. Acad. Sci. USA. 93, 2234-2238.
  5. Communal, C. et al. (2002) Proc. Natl. Acad. Sci. USA. 99, 6252-6256.
  6. Du, J. et al. (2004) J. Clin. Invest. 113, 115-123.
使用例
製品をご使用いただいて研究を発表されましたら、ぜひお知らせください
 
関連製品
4970   β-Actin (13E5) Rabbit mAb

本製品は試験研究用です。

β-Actin Blocking Peptide

Product Pathways

Tools

Applications